2015 was a truly eventful year for Biocartis. It was marked by many transitions, which some see as a prelude to the company becoming a globally active market leader. Biocartis saw the source of its income shift from R&D to sales, as it was the first full financial year since the launch of its diagnostic platform Idylla™. In April 2015, the diagnostics producer delivered a stellar IPO, with the demand for Biocartis shares exceeding the availability by 6.5 times. 2016 is already off to a strong start: After recent collaboration deals with industry greats such as Merck and Amgen, Biocartis seems to be well on its way to becoming a force in the diagnostics market.
2015 was a truly eventful year for Biocartis. It was marked by many transitions, which some see as a prelude to the company becoming a globally active market leader. Biocartis saw the source of its income shift from R&D to sales, as it was the first full financial year since the launch of its diagnostic platform Idylla™. In April 2015, the diagnostics producer delivered a stellar IPO, with the demand for Biocartis shares exceeding the availability by 6.5 times. 2016 is already off to a strong start: After recent collaboration deals with industry greats such as Merck and Amgen, Biocartis seems to be well on its way to becoming a force in the diagnostics market.